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Susceptibility to a clinically signiﬁcant drug hypersensitivity syn-
drome associated with abacavir use seems to have a strong genetic
component. We have previously shown that the presence of HLA-
B*5701 strongly predicts abacavir hypersensitivity and have identi-
ﬁed a potential susceptibility locus within a 300-kb region between
the MEGT1 and C4A6 loci in the central MHC. We now report the
results of ﬁne recombinant genetic mapping in an expanded patient
population of 248 consecutive, fully ascertained, abacavir-exposed
individuals in the Western Australian HIV Cohort Study, in which 18
cases of deﬁnite abacavir hypersensitivity (7.3%) and 230 tolerant
controls were identiﬁed. Haplotype mapping within patients with
allelic markers of the 57.1 ancestral haplotype suggests a suscepti-
bility locus within the 14-kb Hsp70 gene cluster. HLA-B*5701 was
present in 94.4% of hypersensitive cases compared with 1.7% of
controls (odds ratio, 960; P < 0.00001). A haplotypic nonsynonymous
polymorphism of Hsp70-Hom (HspA1L, resulting from the substitu-
tion of residue M493T in the peptide-binding subunit) was found in
combination with HLA-B*5701 in 94.4% of hypersensitive cases and
0.4% of controls (odds ratio, 3,893; P < 0.00001). Individuals with
abacavir hypersensitivity demonstrated increased monocyte tumor
necrosisfactorexpressioninresponsetoexvivoabacavirstimulation,
which was abrogated with CD8 T cell depletion. These data indicate
that the concurrence of HLA-B*5701 and Hsp70-Hom M493T alleles is
necessary for the development of abacavir hypersensitivity, which is
likely to be mediated by an HLA-B*5701-restricted immune response
to abacavir.
ancestral haplotype  microsatellite  human leukocyte antigen 
single-nucleotide polymorphism
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bacavir (1592U89) is a commonly used nucleoside analogue
with potent antiviral activity against HIV type 1. Approxi-
mately 5–9% of patients treated with abacavir develop a hypersen-
sitivity reaction characterized by multisystem involvement that has
proved fatal in rare cases (1–4). Symptoms usually appear within
the first 6 weeks of treatment (median time to onset, 11 days) and
include fever, rash, gastrointestinal symptoms (nausea, vomiting,
diarrhea, or abdominal pain), and lethargy or malaise (3). Symp-
toms related to the hypersensitivity reaction worsen with continued
therapy and improve within 72 h of abacavir discontinuation.
Rechallenging with abacavir after a hypersensitivity reaction typi-
cally results in recurrence of symptoms within hours, with the
potential to induce a more severe clinical syndrome (5).
The involvement of genetic susceptibility factors for this idiosyn-
cratic hypersensitivity syndrome has been suggested by the occur-
rence of the reaction in a small percentage of susceptible abacavir
recipients during a short period of drug exposure, and familial
disposition and decreased incidence are seen in individuals of
African-American origin (6, 7). Consistent with these clinical
observations, a strong predictive association of HLA-B*5701 with
this syndrome has been demonstrated (1, 2), with further evidence
from recombinant haplotype mapping that the susceptibility locus
loci reside specifically with the 57.1 ancestral haplotype (AH),
identified by the haplospecific alleles HLA-B*5701 and C4A6 and
the HLA-DRB1*0701, HLA-DQ3 combination (1). A haplotypic
polymorphism within the tumor necrosis factor (TNF) promoter
region (TNF-238A, associated with the 18.2 and 57.1 AHs) is also
associated with abacavir hypersensitivity (1, 2, 8) and may affect
levels of TNF production, thereby influencing the severity of the
syndrome.
In this study we aimed to further investigate the susceptibility
locusloci associated with abacavir hypersensitivity by using recom-
binant AH mapping, which in our previous analysis identified a
300-kb segment between C4A6 and MEGT1 (G6D) within the
central non-human leukocyte antigen (HLA) region of the MHC.
By haplotype mapping, we can examine disease associations with
highly conserved polymorphic blocks contained throughout the
human genome, particularly within the intensely polymorphic
MHC region; these conserved regions, referred to as polymorphic
frozen blocks, in combination form the AHs observed in different
populations (9–12). Linkage disequilibrium (LD) is extremely high
withinthesameconservedblock,withlimitedornorecombination;
however, recombination events between these regions are not
infrequent, forming the basis for recombinant AH mapping, which
has been used successfully in identifying candidate susceptibility
regions in myasthenia gravis (13). Here, we report that the com-
bination of HLA-B*5701 and a haplotypic polymorphism of Hsp70-
Homishighlypredictiveofabacavirhypersensitivity,thusproviding
a basis for clinically relevant genetic testing as well as for studies of
the mechanistic basis of this hypersensitivity syndrome.
Materials and Methods
Subjects. Retrospective study. The first 200 participants of the West-
ernAustralianHIVCohortStudy,towhomabacavirwasprescribed
before December 31, 2001, and who were included in our previous
study (1), were reclassified based on updated diagnostic criteria.
Clinical diagnostic criteria included the occurrence of classical
symptoms suggestive of multisystem involvement within 6 weeks of
exposure. An appropriate temporal relationship between symptom
resolution and cessation of abacavir was required by these diag-
nostic criteria. In cases where the clinical diagnostic criteria were
fulfilled but an alternative explanation for these symptoms was
present, epicutaneous patch testing and assessment of the specific
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dertaken to clarify the role of abacavir.
Prospective study. Forty-eight individuals exposed to abacavir since
the introduction of prospective genetic testing for HLA-B*5701
andor HLA-DRB1*0701, HLA-DQ3 in December 2001 were
classified by a clinician blinded to the results of genetic analysis
using the updated diagnostic criteria.
Patch Test. Epicutaneous patch testing was undertaken, and reac-
tions (14) were read after 24 and 48 h of application. A positive
resultrequiredabsenceofanallergicresponsetothecontrolvehicle
and demonstration of typical skin changes consisting of erythema
and vesicular rash limited to the patch area. Attempts were made
to patch test all individuals previously classified as abacavir-
hypersensitive cases, including those carrying markers of the 57.1
AH(n14,with9consentingtopatchtesting)aswellasthosewho
did not (n4, with 3 consenting to patch testing). Within the latter
group, three individuals who had an alternative explanation for
their symptoms (concurrent nevirapine therapy) were tested. The
remaining individual who fulfilled diagnostic criteria for abacavir
hypersensitivity in the absence of an alternative explanation had
relocated and was unavailable for further testing.
Within the group clinically designated as ‘‘abacavir hypersensi-
tivity not excluded’’ (n  15) in our previous study (1), three
individuals consented to patch testing. Testing also was performed
on abacavir-tolerant individuals carrying markers of the 57.1 AH
(n  12, with 4 consenting to patch testing), including two who
carried the HLA-B*5701 allele, and on two individuals carrying the
full 57.1 AH (HLA-B*5701, C4A6, and HLA-DRB1*0701, HLA-
DQ3) who had not been exposed to abacavir. Results were negative
in all nine individuals.
Typing of MHC Markers and Assignment of Alleles Specific to the 57.1
AH. Typing of MHC markers was carried out by using standard
genetic assays and sequencing. Single-nucleotide polymorphisms
(SNPs) within genes located in the C4A6–MEGT1 region were
examined by using the National Center for Biotechnology Infor-
mation’s SNP database (www.ncbi.nlm.nih.govSNP). Primers
were designed based on oligonucleotide sequences reported within
the database, and primers and conditions used in the assay are
available on request. A set of well characterized 10 IHWS Epstein–
Barr virus-transformed homozygous B cell lines representing com-
monly occurring European AHs was used to determine alleles
carried on the 57.1 AH. Full-length sequencing across the Hsp70
gene cluster was performed by using overlapping primer pairs.
Measurement of the TNF Response to Abacavir. Intracellular expres-
sionofTNFwasassessedinculturedperipheralbloodmononuclear
cells (PBMCs) grown in the presence and absence of abacavir
sulfate at 4 gml (Ziagen 300-mg commercial grade tablet dis-
solvedinPBS,pH7.4)bymeansofthree-colorflowcytometry(15).
The PBMCs were stained with CD45-ECD, CD14-FITC, or IgG1-
FITC (isotype control) antibodies (all obtained from Immunotech,
Marseille,France)andanalyzedonaCoulterEPICSXL-MCLflow
cytometer by using the LISTMODE FCS2 data analysis program
(Coulter) (15).
CD4 and CD8 Cell Depletion. TNF levels were measured in super-
natantsof1mlofwholebloodculturedintheabsenceandpresence
of abacavir (1 gml, Moravek Biochemicals, Brea, CA) for 24 h at
37°C. Whole blood was depleted of either CD4 or CD8 T cells
by using the Dynabead kit (Dynal, Oslo).
Statistical Analyses. Odds ratios (ORs) were calculated by using
Haldane’s modification, which adds 0.5 to accommodate possible
zero counts (16). Comparisons of demographic and related data in
abacavir-hypersensitive (n  18) and abacavir-tolerant (n  230)
groups were made by using methods previously described (1).
Positive and negative predictive values were calculated within the
retrospective abacavir-exposed cohort (n  200) to exclude poten-
tial confounding caused by the active exclusion of abacavir use
among those carrying 57.1 AH markers in the prospective cohort.
Absolute and relative LD between HLA-B*5701 and Hsp70-Hom
M493T was calculated by using the formulas of Cavalli-Sforza and
Bodmer (17) and Baur and Danilov (18). Significance of LD was
measured by using Fisher’s exact test.
Results
Prevalence of Abacavir Hypersensitivity. In this abacavir-exposed
cohort of 248 individuals, 18 cases with abacavir-hypersensitive
reactions were identified by applying restrictive diagnostic criteria
to identify ‘‘definite’’ cases of hypersensitivity for the purposes of
genetic analysis. This group included 16 definite abacavir-
hypersensitive cases from the previously reported cohort of 200
consecutive abacavir-exposed individuals (1), providing a preva-
lence of 8%. Two other cases were identified among 48 individuals
treated with abacavir after prospective genetic testing.
In our previous study (1), 18 of 200 individuals were clinically
classified as abacavir-hypersensitive. Among these, three individu-
als were receiving concurrent nevirapine therapy, which also may
cause hypersensitive reactions. These patients had a negative re-
sponse to the epicutaneous abacavir skin patch test after 48 h of
application and did not develop a cytokine response to ex vivo
abacavir stimulation (see below). Subsequently, two of these pa-
tients have been rechallenged successfully with abacavir without
developing abacavir hypersensitivity, whereas the third patient has
developed a similar hypersensitive reaction to efavirenz (a drug
within the same class as nevirapine). The negative epicutaneous
patch test results for these three individuals contrast with the
positive results obtained from the nine remaining patients previ-
ously classified as abacavir-hypersensitive who underwent testing
(see Materials and Methods for details), whereas negative results
were obtained in all six abacavir-tolerant individuals tested. On
these grounds, these individuals did not meet the clinical and
immunological diagnostic criteria used in this study. Another
individual from this retrospective cohort (case 14) was classified as
abacavir-hypersensitive, having been clinically designated as ‘‘aba-
cavir hypersensitivity not excluded.’’ This individual developed
typical and severe symptoms that fulfilled the clinical diagnostic
criteriawithinafewdaysofexposuretoabacavir,andnoalternative
explanation for these symptoms was identified. However, the
diagnosis of abacavir hypersensitivity was not made, and the
symptoms gradually resolved over a period of days with intensive
supportive inpatient care at a peripheral hospital. The individual
was therefore likely to have become desensitized by the continued
administration of abacavir and had a negative response to epicu-
taneous patch testing, also in keeping with desensitization to the
drug.
In our previous study (1), a clinical diagnostic category of
‘‘abacavir hypersensitivity not excluded’’ was applied to 15 individ-
uals who developed any symptoms within 6 weeks of the introduc-
tion of abacavir therapy (1), whereas the remaining, abacavir-
tolerant group (n  167) was entirely asymptomatic. One case
described above was classified here as abacavir-hypersensitive. In
the remaining 14 individuals, an alternative cause of symptoms was
present in five cases (three were treated concurrently with efa-
virenz, one with nevirapine, and one with amprenavir). In these
individuals, symptoms did not have an appropriate temporal rela-
tionship with abacavir therapy andor recurred on rechallenge with
the alternative antiretroviral drug. Minor symptoms described by
nine individuals did not fulfill clinical diagnostic criteria. These
cases were therefore classified as abacavir-tolerant for the purposes
of genetic analysis.
Since our initial study (1), 48 individuals have been HLA-typed
before exposure to abacavir. All patients with HLA-B*5701 and
HLA-DRB1*0701, HLA-DQ3 alleles were actively excluded from
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developed a hypersensitive reaction, whereas the remaining 46
patients remained asymptomatic on abacavir therapy. One individ-
ual carried the HLA-B*5701, C4A6, and HLA-DRB1*0701, HLA-
DQ3allelesandwasprescribedabacavirbeforereviewoftheresults
of the HLA typing; another individual, who carried the HLA-
B*5701butnottheC4A6alleleortheHLA-DRB1*0701,HLA-DQ3
combination, made an informed choice to undertake abacavir
therapy. Hence, the incidence of abacavir hypersensitivity among
HLA-B*5701-negative individuals in this prospective cohort was
0% (95% confidence interval, 0–0.075%).
Demographic data for the entire cohort of 248 individuals is
giveninTable1.Withintheabacavir-exposedcohort(n248),214
participants were classified as patients of predominantly European
or Asian Indian descent, and the rest consisted of 11 patients of
African origin, 15 indigenous Australians, and 8 patients of Asian
origin.
MHC Marker Frequency. The distribution of MHC alleles was sig-
nificantly different in the abacavir-hypersensitive, compared with
the abacavir-tolerant, group (Table 2 and Fig. 1). The positive and
negative predictive values presented in Table 2 were calculated for
the retrospective cohort of 200 individuals exposed to abacavir
before December 2001. With regard to alleles specific to the 57.1
AH, HLA-B*5701 was present in 17 of 18 (94.4%) cases with
abacavir hypersensitivity and 4 of 230 (1.7%) abacavir-tolerant
controls [OR  960, P value corrected for the number of alleles
examined (Pc)  0.0001]. C4A6 was present in 14 of 18 (77.8%)
cases and 7 of 230 (3.0%) controls (OR  111, Pc  0.0001), and
the haplospecific combination of HLA-DRB1*0701 and HLA-DQ3
was present in 14 of 18 (77.8%) cases and 11 of 230 (4.8%) controls
(OR  70, Pc  0.0001). Hence, HLA-B*5701 provided the
strongest univariate association with susceptibility to abacavir hy-
persensitivity. When these markers were combined, the previously
described HLA-B*5701, C4A6, HLA-DRB1*0701, HLA-DQ3 hap-
lotype (1) was present in 14 of 18 (77.8%) cases and in none of the
230 controls (OR  1,485, Pc  0.0001).
Mapping of Putative Susceptibility Loci Within the MHC. To map the
putative susceptibility locusloci within the MHC, polymorphic
markers typically found on the 57.1 AH were required. Such
markers within the central MHC region between C4A6 and
MEGT1wereidentifiedbycomparingexamplesofthe57.1AHwith
a subset of well characterized Epstein–Barr virus-transformed cell
lines representative of common European AHs (Fig. 2 and Table
3, which is published as supporting information on the PNAS web
site). The sequenced 8.1, 7.1, and 18.2 AHs (The Wellcome Trust
Sanger Institute MHC Haplotype Project, www.sanger.ac.uk
HGPChr6MHCindex.shtml) also were compared. The carriage
of these markers was examined in the cases (n  18) and controls
(n  12) recombinant for the 57.1 AH to determine the presence
of these markers of the 57.1 AH and to map the extent of the
haplotype within the patients (Fig. 2). Three additional 57.1 AH
recombinant abacavir-tolerant controls subsequently identified in
the prospective cohort were included in Table 2 but not in the fine
mapping study (Fig. 2). With reference to abacavir-hypersensitive
individuals, the centromeric boundary of the putative susceptibility
region was marked by the three SNPs present on the 57.1 AH and
absent in three HLA-B*5701-positive, C4A6-negative recombinant
cases (cases 15–17) suggestive of decay of the 57.1 AH centromeric
of Hsp70.2 in HLA-B*5701-negative individuals (Fig. 2). One of
these cases (case 16) carried the HLA-B*5701 allele and the Hsp70
region of the 57.1 AH but lacked the region from snRNP to
MEGT1, expressing non-57.1 AH alleles at one SNP and two
microsatellite loci in this region. The translated sequences of
Hsp70.1 and Hsp70.2 were similar in abacavir-hypersensitive indi-
viduals (cases 15–17) and controls with recombinant 57.1 AHs
(cases 19–22) and were therefore excluded as candidate suscepti-
bility loci.
The presence of previously reported nonsynonymous substitu-
tions within genes in the region telomeric of the Hsp70 cluster
between MEGT1 and snRNP was examined in the 57.1 AH ho-
mozygous cell line and compared with the MHC sequence of the
8.1, 7.1, and 18.2 AH sequences submitted to GenBank (Table 3).
We did not identify unique nonsynonymous substitutions in this
relatively nonpolymorphic interval. Hence, mapping of recombi-
Table 1. Details of patient demographics and immunological status in the abacavir-hypersensitive and -tolerant groups
Sex, n (%) Ethnicity, n (%)
Mean age,
years (SD)
Mean CD4
count, cells
per l (SD)
Mean CD8
proportion, % (SD) MF EN E
Hypersensitive, n  18 15 (83) 3 (17) 18 (100) 0 45.0 (10.3) 446 (299) 51.8 (12.1)
Tolerant, n  230 197 (86) 33 (14.3) 196 (85) 34 (15) 42.6 (10.3) 435 (284) 51.5 (12.1)
Pvaluesfollowformale(M)abacavir-hypersensitiveand-tolerantindividuals,abacavir-hypersensitiveand-tolerantindividualsofEuropeandescent(E),mean
age, mean CD4 T cell count, and mean CD8 T cell proportion: 0.73, 0.15, 0.35, 0.85, and 0.92, respectively. F, female; NE, individuals of non-European descent.
Table 2. MHC alleles observed within the abacavir-hypersensitive and -tolerant controls
MHC marker
Hypersensitive,
n (%)
Tolerant,
n (%) OR
Positive predictive
value, %
Negative predictive
value, %
HLA-B*5701 17 (94.4) 4 (1.7) 960.0 78.9 99.4
C4A6 14 (77.8) 7 (3.0) 111.5 72.2 98.3
HLA-DRB1*0701, HLA-DQ3 14 (77.8) 11 (4.8) 69.7 65.0 98.3
Hsp70-Hom M493T 17 (94.4) 51 (22.2) 59.7 25.4 99.3
HLA-B*5701, C4A6 14 (77.8) 0 1,485.0 100.0 98.4
HLA-B*5701, HLA-DRB1*0701, HLA-DQ3 14 (77.8) 0 1,485.0 100.0 98.4
HLA-B*5701, Hsp70-Hom M493T 17 (94.4) 1 (0.43) 3,893.0 93.8 99.5
TheHLA-B*5701,HLA-DRB1*0701,HLA-DQ3,andC4A6typingwasperformedasdescribedinourpreviousstudy(1).TheHsp70-Hom
M493T SNPs were typed by using a combination of restriction fragment-length polymorphism and sequence-speciﬁc primer polymor-
phism assays. For all MHC markers, corrected P values are 0.00001. Positive and negative predictive values were calculated within the
retrospectiveabacavir-exposedcohort(n200),toexcludepotentialconfoundingcausedbytheactiveexclusionofabacaviruseamong
those carrying 57.1 AH markers in the prospective cohort.
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identifiedacandidatesusceptibilityregionincludingtheHsp70gene
cluster that narrowed the putative susceptibility region to the
Hsp70-Hom locus. The only nucleotide substitution in the Hsp70-
Hom gene identified in most of the abacavir-hypersensitive cases
(94.4%) involvedaTt oCtransition, which results in a change from
methionine to threonine at amino acid residue 493 [hereafter
referred to as M493T but also known as the Hsp70-Hom 2437CT
allele (19) or rs2227956CT (www.ncbi.nlm.nih.govSNP
snpref.cgi?locusId3305]. The Hsp70-Hom M493T allele was as-
sessed in all 248 patients of the cohort by using an allele-specific
sequence-specific primer andor the standard NcoI restriction
fragment-length polymorphism assays. We observed that the
Hsp70-Hom M493T allele, carried on the 57.1 AH, was detected in
94.4%ofthehypersensitivegroupcomparedwith22.2%oftolerant
controls (17 of 18 individuals vs. 51 of 230 individuals, OR  59.7,
Pc  0.00001). However, in combination with HLA-B*5701,t h e
Hsp70-Hom M493T allele was strongly associated with abacavir
hypersensitivity (17 of 18 individuals vs. 1 of 230 individuals, OR 
3,893, Pc  0.00001) (Table 2). Consistent with a role for both of
these genetic markers in determining susceptibility to abacavir
hypersensitivity, inclusion of the Hsp70-Hom M493T, in addition to
the HLA-B*5701, allele provided significantly improved discrimi-
nationbetweenabacavir-hypersensitivecasesand-tolerantcontrols
compared with the HLA-B*5701 allele alone (P  0.003, Fisher’s
exact test).
Expression of Inflammatory Cytokine TNF in Abacavir-Hypersensitive
Individuals. Cytokine response was examined by measuring intra-
cellular TNF levels in cultures of abacavir- or phorbol 12-myristate
13-acetate-stimulated PBMCs from abacavir-hypersensitive, -tol-
erant, and unexposed HIV-positive patients. The proportion of
monocytes accumulating TNF was measured in a rapid (4 h)
abacavir-stimulated ex vivo-cultured PBMC assay. The proportion
of TNF-positive cells was higher in patients with abacavir hyper-
sensitivity (n  8) than in abacavir-tolerant controls (n  9) with
a median 13.4-fold increase [interquartile range (IQR)  13.0]
compared with a median 8.9-fold decrease in proportion of TNF-
positive cells in tolerant controls (IQR  24.1, P  0.008, Mann–
Whitney test) (data not shown). The three individuals classified as
abacavir-tolerant on the basis of a negative epicutaneous patch test
and an alternative explanation for their symptoms also had no
increase in TNF-positive cells in response to abacavir stimulation.
Phenotype of T Cells Expressing TNF After Abacavir Stimulation.
Further phenotypic characterization of the T cell response to
abacavir was carried out on whole blood cultures of two patients
who were selected for analysis because they both carried the
predictive HLA-B*5701 and Hsp70-Hom M493T alleles yet were
divergent in their clinical responses to abacavir. Definite abacavir
hypersensitivityoccurredincase17within1weekofdrugexposure,
whereas case 21 tolerated this drug without any clinical symptoms
suggestive of hypersensitivity. Involvement of CD4 and CD8 T
cells in the secretion of TNF in culture supernatants was deter-
mined after stimulation with abacavir. Extracellular levels of TNF
Fig. 1. Increased frequency of markers of the 57.1 AH among abacavir-
hypersensitive individuals. As shown from left to right, MHC markers including
HLA-B*5701, C4A6, and HLA-DR7, HLA-DQ3 were compared in the healthy
controls of the Western Australian Bone Marrow Donor Registry (n  3,212),
HIV-positive cohort (n  381), abacavir-exposed cohort (n  248), abacavir-
hypersensitive group (n  18), and abacavir-tolerant group (n  230).
Fig. 2. Recombinant mapping identiﬁes
the Hsp70 subgenomic region in combina-
tion with HLA-B*5701 as the most parsimo-
nious susceptibility region to abacavir hyper-
sensitivity. The region carrying the putative
susceptibility loci has been mapped to the
MHC class III region on chromosome 6p21.3
(1). Typing of genetic markers within the
C4A6–MEGT1intervalpresentonthe57.1AH
was carried out on abacavir-hypersensitive
cases (n  18) and abacavir-tolerant controls
(n  12) recombinant for the 57.1 AH. For
each individual, shading indicates presence
of the marker carried by the 57.1 AH.
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abacavir-hypersensitive individual compared with those of the
abacavir-tolerant control (Fig. 3). In addition, TNF levels were
attenuated in the abacavir-stimulated blood of this abacavir-
hypersensitivepatientwhenCD8Tcellsweredepleted,compared
with undepleted or CD4 T cell-depleted cultures, suggesting the
involvement of MHC class I molecules and CD8 T cells in the
development of this immune reaction.
Discussion
In this study we have used recombinant haplotype mapping to
confirm a strong genetic association between the 57.1 AH and
definite abacavir hypersensitivity, with further evidence that the
concurrence of the HLA-B*5701 allele and a haplotypic variant
of the Hsp70-Hom allele represents a highly predictive marker of
susceptibility. Through the application of a restrictive definition
of definite hypersensitivity, this study is likely to have selected
cases with a highly stereotypical immunological response to
abacavir exposure, and it must be acknowledged that abacavir
also was discontinued in nine individuals (3.6%) with minor
symptoms that were not diagnostic of definite abacavir hyper-
sensitivity. These data are consistent with another study involv-
ing a fully ascertained cohort of abacavir-exposed individuals in
France (n  331), in which the prevalence of likely hypersensi-
tivity was 8.5%, whereas a further 4.2% ceased abacavir treat-
ment within 6 months because of doubtful hypersensitivity
reactions (4).
Severallinesofevidencestronglysuggesttheinvolvementofboth
Hsp70-Hom and HLA-B*5701. The centromeric boundary of the
susceptibility region 3 of Hsp70.2 was demarcated by the presence
of three non-57.1 AH alleles, one in each of the recombinant
abacavir-hypersensitive individuals (cases 15–17). In addition, the
telomeric end of the hypersensitivity region is flanked by snRNP,a s
anabacavir-hypersensitiveindividual(case16)carriednon-57.1AH
alleles between snRNP and MEGT1 (identified by non-57.1 AH
alleles at two microsatellites and one SNP loci). Additional non-
synonymous polymorphisms in genes within the snRNP–MEGT1
region were not detected in the homozygous 57.1 AH cell line. A
unique gene carried on the 57.1 AH was not identified in the
Hsp70.2–Hsp70-Hom region after direct sequencing, and the iden-
tical translated sequences of Hsp70.1 and Hsp70.2 genes carried in
the homozygous 57.1 AH cell line and by abacavir-tolerant controls
carrying HLA-B*5701 (cases 19–22) also eliminate these genes as
possiblecandidates.However,ourmappingstudiesarebasedonthe
presence of reported microsatellite and SNP analysis in a limited
number of patients recombinant for the 57.1 AH. Despite our
extensive search for informative SNPs by screening and direct
sequencing, there may be an unidentified gene within the HLA-
B*5701–Hsp70-Hom M493T interval that confers susceptibility to
abacavir hypersensitivity. Moreover, there may be other determi-
nants in addition to HLA-B*5701 and Hsp70-Hom M493T required
for the manifestation of this syndrome.
In this study, the presence of HLA-B*5701 provides specificity,
whereas the combination of HLA-B*5701 and Hsp70-Hom M493T
alleles, which are in strong LD in our abacavir-exposed cohort
(LD  0.030, P  0.00001, relative LD  0.82), significantly
increased the ability to discriminate between hypersensitive cases
and tolerant controls compared with HLA-B*5701 testing alone;
the combination occurred in 94.4% of patients and in only 0.4% of
controls. Hence, in this study, susceptibility to abacavir hypersen-
sitivity appears to be conferred by Hsp70-Hom M493T in concur-
rence with HLA-B*5701 within the 57.1 AH. However, the small
number of informative patients recombinant for the 57.1 AH
necessitates further functional studies to confirm an interaction of
theallelicproductsofthetwoloci.TheinvolvementofHLA-B*5701
in determining a MHC class I-restricted immune response to
abacavir is in keeping with the CD8 T cell-dependent production
of TNF by mononuclear cells demonstrated in this study and with
the prominent CD8 cell infiltrate associated previously with
epicutaneous patch testing (14). In addition, patients with a higher
CD8 T cell count (850 cells) at the time of exposure to abacavir
have an increased risk of developing hypersensitivity (20). HLA-
B*5701 is an effective antigen-presentation molecule and is asso-
ciated with slow progression of HIV and induction of potent
cytotoxicTlymphocyteresponses(21),andHsp70proteinsarealso
known to bind peptides (22) and to play a role in antigen presen-
tation, particularly cross presentation of exogenous antigen to
CD8 T cells (23–28) and cytokine response (29). In this context,
the Hsp70-Hom M493T polymorphism is predicted to affect sub-
strate binding, because residue 493 resides on the floor of the
peptide-binding domain of the homologous Hsc70 molecule (23).
Determining the specific role of residue 493 in contributing to the
Fig. 4. Pathogenic model for the generation of a hypersensitive response to
abacavir.Constitutivelyexpressed(19)Hsp70-Hommoleculesmayfacilitateload-
ing of an abacavir haptenated peptide onto HLA-B*5701. Abacavir undergoes
sequential intracellular phosphorylation to carbovir monophosphate (CBV-MP)
and carbovir triphosphate (CBV-TP) and subsequently inhibits HIV reverse tran-
scriptase (HIV-RT).
Fig. 3. Abrogation of secreted TNF levels in supernatants of abacavir-
stimulated whole blood cultures depleted of CD8 T cells. Secreted TNF was
measured by the Chemiluminescent IMMULITE (Diagnostic Products, Los An-
geles) method in whole blood culture supernatants from an abacavir (ABC)-
hypersensitive(HSR)andanabacavir-tolerantindividualcarryingHLA-B*5701
and Hsp70-Hom M493T alleles after stimulation with (ﬁlled bars, abacavir-
hypersensitive; ﬁlled stippled bar, abacavir-tolerant) or without (open bars,
abacavir-hypersensitive; open stippled bar, abacavir-tolerant) abacavir.
4184  www.pnas.orgcgidoi10.1073pnas.0307067101 Martin et al.specificityofpeptidebindingandorantigenprocessingwillrequire
biochemical and structural analysis. However, it is tempting to
speculate that HLA-B*5701 and Hsp70-Hom cooperate during
antigen presentation to confer susceptibility to abacavir hypersen-
sitivity(seeproposedmodelinFig.4).Preliminarydatasuggestthat
indeed HLA-B57 and Hsp70 molecules colocalize within discrete
vesicles in the CD14 monocyte population of ex vivo-cultured
abacavir-exposed PBMCs of abacavir-hypersensitive patients
(A.M.M., C.A.A., and S.M., unpublished work).
We hypothesize that abacavir or its metabolites may be involved
in the haptenation of endogenous peptides and subsequent pre-
sentation of ‘‘altered self’’ in the context of HLA-B*5701, thus
inducing vigorous T cell responses. It is noteworthy that Hsp70-
associated peptides can furnish MHC class I-restricted determi-
nants to class I molecules (22–28). It is therefore conceivable that
Hsp70 plays a direct role in the selection of HLA-B*5701-restricted
peptide substrates that are potentially haptenated through an
abacavir-dependent mechanism. Haptenation of proteins and cell-
surface peptides is well documented and can lead to MHC-
restricted T cell immunity resembling auto- and alloimmune re-
sponses(28).TheinvolvementofHLAmoleculesinpresentationof
drugs andor drug metabolites in the pathogenesis of a number of
drug hypersensitivity reactions has been previously reported (30–
33), although this is one of the few reports implicating HLA class
I molecules in the development of drug hypersensitivity. In the case
of abacavir, different chemical pathways could contribute to hap-
tenation reactions, although the generation of a carboxylate deriv-
ative after oxidation of primary  alcohol (34) may be implicated,
as this reaction may proceed by means of a reactive aldehyde
intermediate that could mediate covalent binding to proteins and
peptidesthroughaSchiffbase-typereaction(34)or1,4nucleophilic
addition.
The presence of both HLA-B*5701 and the Hsp70-Hom M493T
variant in one abacavir-tolerant individual, who also demonstrated
an absent immunological response to ex vivo abacavir stimulation,
suggests that there may be other necessary determinants involved
in the etiology of this syndrome. Further studies are needed to
investigate the functional determinants of abacavir-specific antigen
processing and presentation, which should clarify the pathways
involved, and the role of modulating factors.
We also noted that, although increased intracellular TNF ex-
pression in response to abacavir stimulation occurred in most
patients with a hypersensitivity reaction, two patients with definite
hypersensitivity did not have detectable increases in TNF expres-
sion. This is unlikely to be attributable to clinical misclassification,
because both patients had positive epicutaneous patch test results
and one had previously developed a diagnostic syndrome on a
second occasion after being rechallenged with abacavir. Therefore,
measurement of the immunological response to ex vivo abacavir
stimulation according to our method does not have sufficient
sensitivity to be used as a basis for rechallenging a patient with
abacavir in cases where a previous hypersensitivity reaction is
suspected.
From a clinical perspective, these data indicate that the prospec-
tive use of a genetic test involving HLA-B*5701 alone or in
combination with the Hsp70-Hom M493T variant would reduce the
prevalence of definite abacavir hypersensitivity in our cohort from
8% to 0.4%. When using HLA-B*5701 alone, an estimated 1.6% of
the tested population would be inappropriately denied access to
abacavir. Testing for the presence of HLA-B*5701 and the Hsp70-
Hom M493T variant would reduce this percentage to 0.4%, based
on our data. Given the HLA-B*5701 phenotype frequency of 8.5%
in our cohort, we can predict that 14 individuals would need to be
screened for HLA-B*5701 to prevent one case of abacavir hyper-
sensitivity. Taken together, these data indicate that prospective
genetic testing for abacavir hypersensitivity is likely to be highly
predictive, and, at least in populations of European descent, in
which the HLA-B*5701 allele is relatively common, cost-
effective (35).
In conclusion, we have identified the HLA-B*5701 and Hsp70-
Hom M493T alleles as highly predictive genetic markers of suscep-
tibility to abacavir hypersensitivity. These findings have significant
implications both in terms of the clinical management of abacavir-
exposed HIV-infected patients and the elucidation of basic patho-
physiological mechanisms underlying this and other idiosyncratic
drug hypersensitivity reactions.
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